COVID-19
Outpatient Management

Outpatient Management

Outpatient Treatments

  • Paxlovid is preferred 1st line for all patients who meet criteria for use
  • Molnupiravir is available when Paxlovid is not clinically appropriate
  • Bebtelovimab is no longer authorized for use
  • Ambulatory remdesivir is not available

Home Delivery Option

The prescription home delivery service, Phox Health, is available for a fee through the MHS retail pharmacies in both regions. See MHS-Med-Delivery-Tip-Sheet for instructions

VTE Prophylaxis

  • Physical activity/ambulation should be encouraged as tolerated to reduce the risks of DVT/PE
    • Continue current medications (including previously prescribed anticoagulation for other conditions)
    • Patients should not start or change aspirin or other antiplatelet dosing
    • Pharmacologic VTE prophylaxis is not recommended given the low incidence (<1.5%) of VTE in ambulatory COVID-19 patients

Note: Evusheld™ - No Longer Available

The EUA for Evusheld was revoked by the FDA on 1-26-23. FDA announcement - Evusheld